Navigation Links
Genta Announces Senior Management Changes
Date:2/22/2008

ith respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:
-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to regain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annu
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider ... pharmaceutical and medical device industries, has announced a laboratory ... company has consolidated its histology and tissue analysis operations ... CO, just north of Denver. The new addresses ... Ave., Suite 100, Westminster, CO 80021 , Tissue Image ...
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Isotope Ratio Mass Spectrometer Industry Report 2014" report ... Isotope Ratio Mass Spectrometer Industry Report 2014 is a ... the global isotope ratio mass spectrometer industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, ... delivery technologies, today announced that it has been selected ... & Industry Association,s 2014 Awards for Excellence ... by an independent panel of judges from SCORE (Counselors ... Award winners will be honored at a gala event ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... July 31 Vista Partners announced today,that it ... drug,candidates, which target billion dollar markets, are progressing ... will present Phase 2 results for,Convivia(TM) sometime in ... FDA approval,of Delayed Release (DR) Cysteamine for the ...
... Iceland, July 31 deCODE genetics,Inc. (Nasdaq: DCGN ... quarter,2008 financial results in a press release to be ... market in New York. The company will host a ... and recent,operating highlights on Thursday, August 7, at 8am ...
... 31 InNexus,Biotechnology Inc., (TSX VENTURE: IXS; ... drug development company commercializing the,next generation of ... Linking,(DXL(TM)) technology, will present at IBC,s 13th ... Innovative Therapeutics (DDT) Conference being,held in Boston ...
Cached Biology Technology:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP) 2deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results 2InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th 2
(Date:8/26/2014)... Scientists succeeded in obtaining an unprecedented view of ... in a range of neurological illnesses, including Alzheimer,s ... injuries associated with stroke. , The team of ... U.S. Department of Energy,s Advanced Photon Source at ... of the intact NMDA (N-methyl, D-aspartate) receptor should ...
(Date:8/26/2014)... While the importance of enteral nutrition (EN), or feeding ... is well understood, underfeeding is still common. A practice ... be interrupted by tests, procedures, or emergencies. Changing to ... volume per day, could reduce underfeeding. , Such a ... according to a quality improvement audit published in the ...
(Date:8/26/2014)... suggests the planet can produce much more land-plant biomass ... grains and other terrestrial plant parts than previously ... Environmental Science and Technology , recalculates the theoretical limit ... much higher than many current estimates allow. , "When ... you have to make some simplifying assumptions," said University ...
Breaking Biology News(10 mins):Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 2Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 3Study: Earth can sustain more terrestrial plant growth than previously thought 2Study: Earth can sustain more terrestrial plant growth than previously thought 3
... Louis are bringing the minimalist approach to medical ... technology with a smartphone, enabling a compact, mobile ... fits in the palm of a hand. ... of Computer Science and Engineering, and David Zar, ...
... occur under climate change scenarios has led many scientists to ... But a new study in the May issue of ... the types of plants growing in an area could override ... Higuera of Montana State University and his colleagues show that ...
... environmental scientist from the University of East Anglia (UEA) ... contribution to oceanography. Prof Karen Heywood will ... of the European Geophysical Union assembly in Vienna on ... 25 years of successful field work at sea, Prof ...
Cached Biology News:Ultrasound imaging now possible with a smartphone 2Ultrasound imaging now possible with a smartphone 3Plants could override climate change effects on wildfires 2
...
Contains L-glutamine....
... Resolution - Efficiently separates ... to 1000 bp. It ... PCR fragments, small DNA ... enzyme digestion, and double-stranded ...
...
Biology Products: